CCO Independent Conference Highlights of the 2024 ASCO Annual Meeting

Review slidesets, on-demand webcasts, and expert analyses of key data from the 2024 ASCO Annual Meeting.

Share

Program Content

Activities

Key Studies From Chicago 2024
An Expert’s Guide to ASCO 2024: Preview of the Top Abstracts
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: May 30, 2024

Expires: May 29, 2025

Activities

NATALEE N0 Subgroup
NATALEE: Subgroup Analysis of Adjuvant Ribociclib + NSAI vs NSAI Alone in Patients With Stage II/III Node-Negative HR+/HER2- EBC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 02, 2024

Expires: June 01, 2025

postMONARCH
postMONARCH: Abemaciclib + Fulvestrant vs Fulvestrant Monotherapy for HR+/HER2- Advanced BC After Progression on CDK4/6 Inhibitor + ET
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 03, 2024

Expires: June 02, 2025

SACI-IO HR+
SACI-IO HR+: Phase II Trial of Sacituzumab Govitecan ± Pembrolizumab in HR+/HER2- Metastatic Breast Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2024

Expires: June 03, 2025

DESTINY-Breast07
DESTINY-Breast07: Trastuzumab Deruxtecan ± Pertuzumab for Previously Untreated HER2+ Metastatic Breast Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2024

Expires: June 03, 2025

DESTINY-Breast06
DESTINY-Breast06: Phase III Trial of Trastuzumab Deruxtecan vs Chemotherapy in Previously Treated HR+/HER2-Low or Ultralow MBC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2024

Expires: June 04, 2025

I-SPY 2.2 Dato-DXd + Durva
I-SPY 2.2: Neoadjuvant Datopotamab Deruxtecan Plus Durvalumab in High-Risk Stage II-III HER2-Negative Breast Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2024

Expires: June 06, 2025

A BRAVE
A-BRAVE: Phase III Trial of Adjuvant Avelumab vs Observation in Patients With Early TNBC With Residual Disease Post Neoadjuvant CT or at High Risk After Surgery and Adjuvant CT
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2024

Expires: June 06, 2025

ASCO to Clinic: Breast Cancer
Conference to Clinic: Breast Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 21, 2024

Expires: June 20, 2025

Activities

ASC4FIRST
ASC4FIRST: Phase III Trial of Asciminib vs Investigator-Selected TKIs in Newly Diagnosed CML
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 03, 2024

Expires: June 02, 2025

DREAMM-8
DREAMM-8: Phase III Trial of Belantamab Mafodotin + Pomalidomide/Dexamethasone (BPd) vs Pomalidomide + Bortezomib/Dexamethasone (PVd) in RRMM
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2024

Expires: June 03, 2025

Integrated Palliative Care in AML/MDS
Integration of Palliative and Oncology Care for Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Treated With Nonintensive Therapy
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2024

Expires: June 03, 2025

MANIFEST 2
MANIFEST-2 Update: Phase III Trial of Pelabresib Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2024

Expires: June 04, 2025

Pirtobrutinib Prior to CAR T Therapy
Pirtobrutinib Prior to Bispecific Anti-CD20/CD19 CAR T-Cell Therapy in Patients With Relapsed/Refractory Lymphoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2024

Expires: June 04, 2025

DEB: Tucidinostat + RCHOP in DLBCL
Phase III DEB Trial: Interim Analysis of Tucidinostat + R-CHOP vs R-CHOP Alone as 1L Tx in MYC and BCL2 Double-Expressing DLBCL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2024

Expires: June 05, 2025

ECHELON-3
ECHELON-3: Phase III, Placebo-Controlled Trial of Brentuximab Vedotin in Combination With Lenalidomide and Rituximab in R/R DLBCL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2024

Expires: June 05, 2025

FELIX: Obe Cel in Adult B ALL
FELIX: Phase Ib/II Study of Obecabtagene Autoleucel in Adults With Relapsed/Refractory B-Cell ALL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2024

Expires: June 05, 2025

Cytopenias and MNs After CAR T Therapy
Cytopenias and Myeloid Neoplasms After CAR T-Cell Therapies
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2024

Expires: June 05, 2025

IMROZ
IMROZ: Phase III Study of Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone vs Bortezomib, Lenalidomide, and Dexamethasone for Transplant-Ineligible, Newly Diagnosed MM
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2024

Expires: June 05, 2025

BENEFIT IsaVRd vs IsaRd
BENEFIT/IFM 2020-05: Phase III Trial of Isa-VRd vs Isa-Rd in Patients With Transplant-Ineligible NDMM
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2024

Expires: June 06, 2025

PERSEUS MRD Analysis
Phase III PERSEUS: MRD Analysis of VRd ± Daratumumab in Newly Diagnosed Multiple Myeloma Eligible for ASCT
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2024

Expires: June 06, 2025

ASCO 2024: Leukemias
Conference to Clinic: Leukemias
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 18, 2024

Expires: June 17, 2025

Lymphomas
Conference to Clinic: Lymphomas
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 20, 2024

Expires: June 19, 2025

Multiple Myeloma
Conference to Clinic: Multiple Myeloma
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 20, 2024

Expires: June 19, 2025

Activities

EVOKE 01
EVOKE-01: Phase III Trial of Sacituzumab Govitecan vs Docetaxel in Patients With Previously Treated Advanced NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 02, 2024

Expires: June 01, 2025

CROWN 5 Yr Update
Phase III CROWN: 5-Yr Update of First-line Lorlatinib vs Crizotinib in Advanced ALK-Positive NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 03, 2024

Expires: June 02, 2025

KRYSTAL 12
KRYSTAL-12: Phase III Trial of Adagrasib vs Docetaxel in Previously Treated Advanced KRASG12C- Mutated NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2024

Expires: June 03, 2025

LAURA: Osimertinib Consolidation
LAURA: Phase III Trial of Osimertinib vs Placebo After Definitive Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2024

Expires: June 03, 2025

ADRIATIC
ADRIATIC: Phase III Trial of Consolidation Therapy With Durvalumab for Limited-Stage Small-Cell Lung Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2024

Expires: June 03, 2025

PALOMA-3 SC Amivantamab
PALOMA-3: Phase III Noninferiority Trial of SC Amivantamab vs IV Amivantamab Each With Lazertinib in Progressive Advanced EGFR-Mutated NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2024

Expires: June 03, 2025

DESTINY Lung02 Final Analysis
DESTINY-Lung02: Final Analysis of Trastuzumab Deruxtecan in Previously Treated HER2-Mutated Metastatic NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2024

Expires: June 05, 2025

Beamion LUNG 1
Beamion LUNG-1 Phase Ia/Ib Study: Updated Results of HER2 TKI Zongertinib in Patients With Advanced NSCLC or Other Solid Tumors With HER2 Aberrations
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2024

Expires: June 05, 2025

WU KONG1
WU-KONG1: Primary Analysis of a Phase II Study of Sunvozertinib in Patients With Previously Treated Advanced NSCLC and an EGFR Exon 20 Insertion Mutations
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2024

Expires: June 05, 2025

REACH PC
REACH PC: A Comparison of Efficacy of Telehealth vs In-Person Visits for Delivery of Early Palliative Care for Patients With Advanced NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2024

Expires: June 06, 2025

ASCO to Clinic: Lung Cancers
Conference to Clinic: Lung Cancers
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 21, 2024

Expires: June 20, 2025

Activities

ASCO to Clinic: Skin Cancer
Conference to Clinic: Skin Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 20, 2024

Expires: June 19, 2025

Activities

Genitourinary Cancers
Conference to Clinic: Genitourinary Cancers
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 20, 2024

Expires: June 19, 2025

Activities

RUBY dMMR Post Hoc Analysis
RUBY Post Hoc Analysis: Survival Outcomes With Dostarlimab Plus Chemotherapy by Type of MMR Deficiency in Patients With Endometrial Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 25, 2024

Expires: June 24, 2025

Faculty

cover img faculity

Allison Betof Warner, MD, PhD

Assistant Professor of Medicine (Oncology)
Director, Melanoma Medical Oncology Program
Director, Solid Tumor Cellular Therapy 
Leader, Melanoma & Cutaneous Oncology Clinical Research Group
Stanford University School of Medicine
Stanford, California

cover img faculity

Sara A. Hurvitz, MD, FACP

Professor of Medicine
Head, Division of Hematology and Oncology
Department of Medicine, UW Medicine
Senior Vice President
Clinical Research Division
Fred Hutchinson Cancer Center
Seattle, Washington

cover img faculity

Kevin Kalinsky, MD, MS

Division Director, Medical Oncology
Professor, Department of Hematology and Medical Oncology
Winship Cancer Institute at Emory University
Atlanta, Georgia

cover img faculity

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Mayo Clinic
Rochester, Minnesota

cover img faculity

Natasha Leighl, MD, MMSc, FRCPC, FASCO

Lung Medical Oncology Site Lead
OSI Pharmaceuticals Foundation Chair
Princess Margaret Cancer Centre
Professor of Medicine
University of Toronto
Toronto, Canada

cover img faculity

Rana R. McKay, MD

Associate Professor of Medical Oncology and Urology
Associate Director, Clinical Sciences
Co-Lead, Genitourinary Malignancies Program
Moores Cancer Center
University of California San Diego
La Jolla, California

cover img faculity

Zofia Piotrowska, MD

Assistant Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

cover img faculity

Jeffrey P. Sharman, MD

Medical Director of Hematology Research
Sarah Cannon at Willamette Valley Cancer Institute
Eugene, Oregon

cover img faculity

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Breast Cancer: Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Novartis Pharmaceuticals Corporation.

Lung Cancer: Supported by educational grants from AstraZeneca; Daiichi Sankyo, Inc.; and Gilead Sciences, Inc.

Hematologic Malignancies: Supported by educational grants from GSK, Lilly, Novartis Pharmaceuticals Corporation, and Sanofi.

Melanoma and Other Skin Cancers: Supported by an educational grant from Merck Sharp & Dohme LLC.

Genitourinary Cancer: Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Gynecologic Malignancies: Supported by an educational grant from GSK.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GSK

Lilly

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Sanofi